eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 56
Original paper

The role of ceramide and SEW 2871 in the transcription of enzymes involved in amyloid b precursor protein metabolism in an experimental model of Alzheimer’s disease

Kinga Czubowicz, Sylwia Wójtowicz, Przemysław Leonard Wencel, Robert Piotr Strosznajder

Folia Neuropathol 2018; 56 (3): 196-205
Online publish date: 2018/09/28
Article file
- The role Czubowicz.pdf  [0.37 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


The metabolic turnover of sphingolipids produces several signaling molecules that profoundly affect the proliferation, differentiation and death of cells. In particular, a lot of evidence is available that defines diversified roles of ceramide and sphingosine-1-phosphate (S1P) in cell death and survival [6,7,13,33,38]. For the last two decades ceramides have been most intensively studied in relation to different types of cell death signaling. Enhanced ceramides’ levels have been observed in Alzheimer’s disease (AD) and in other neurodegenerative disorders [10,34,61]. Our last results demonstrated the molecular alterations evoked by ceramides in neuronal cells [11]. In physiological conditions ceramides do not accumulate, but they are used as a precursor for the synthesis of other sphingolipids such as sphingomyelin, glycosphingolipids, sphingosine and pro-survival S1P. The alterations in the ceramides’ level may occur during the following processes: de novo synthesis, activation of enzymes that catalyze its synthesis from sphingosine and hydrolysis of sphingomyelin with participation of acid (aSMase) and neutral (nSMase) sphingomyelinases [15,23].
Ceramides may be broken down by ceramidases, which leads to the formation of sphingosine that subsequently can be phosphorylated by sphingosine kinases (Sphk1 and Sphk2) to S1P. S1P is an important bioactive phosphosphingolipid recognized as a critical regulator of a variety of signaling pathways, which play major roles in diverse physiological and pathophysiological processes. S1P is involved in many cellular processes including survival, proliferation, adhesion, migration and differentiation [13]. It is known that S1P acts in an autocrine/paracrine manner via a family of five S1P-specific cell-surface G-protein-coupled receptors (GPCRs, termed S1PR1-5) [30,48]. The recent studies have pointed out the importance of S1P signaling dysregulation in pathogenesis of AD [16,54]. In the last decade, the role of sphingolipids in the cellular survival was described using the sphingolipid rheostat model where pro-apoptotic ceramide and sphingosine are offset by the pro-survival signaling of their closely linked metabolites S1P and ceramide-1-phosphate (C1P). The disturbances of balance between ceramide and S1P are observed in many diseases such as AD, multiple sclerosis, ischemia [16,40,55]. Both of those bioactive sphingolipids are engaged directly or indirectly in the regulation of amyloid  peptides (A) metabolism. A is released from -amyloid precursor protein (APP), a membrane protein involved in regulation of synapse formation, neuronal growth and repair. APP is metabolized by two separate pathways: nonamyloidogenic and amyloidogenic. In the nonamyloidogenic pathway, - and -secretases are responsible for APP degradation to peptide p3 and APP. Several zinc metalloproteinases, including ADAM10, can mediate APP cleavage at -secretase sites [1]. In the amyloidogenic pathway, APP is degraded by -site APP-cleaving enzyme 1 (BACE1) and by -secretase to A. The -secretase is a tetrameric protein complex that contains two presenilins (PSEN1 and PSEN2), the most important components of this secretase [4,26,62].
Ceramides and A share many common features, especially in induction of oxidative stress and inflammatory response. Both of them are responsible for activation of inducible NO synthase (iNOS) and proinflammatory cytokines tumor necrosis factor (TNF)-, interleukin (IL)-1 [19]. Elevated ceramides’ levels are observed in the AD brain and blood samples [10,35,61]. Panchal et al. observed that Cer(d18:1/18:0) and Cer(d18:1/20:0) ceramides’ levels are enriched within senile plaques in comparison with neutrophils [44]. The authors suggest that the increased sphingomyelin hydrolysis leads to ceramide accumulation. Moreover, the elevated aSMase and nSMase activities and gene expressions are observed in AD brains [12,18,45]. Additionally, A generation may be also regulated indirectly by ceramides. Ceramides could post-translationally stabilize the -secretase (BACE1), increase its half-life and thereby enhance A biogenesis [46]. Recent data of Takasugi et al. study suggest that a synthetic ceramide analogue can be responsible for elevated A production via modulation of -secretase production [50]. Reversely, A peptides could stimulate ceramide synthesis by activation of nSMase [18,28].
It is common knowledge that oxidative stressors play a crucial role in the pathology of neurodegenerative diseases. Oxidative stress evoked by A peptides may lead to disturbance of many key processes involved in regulation of the cell viability and death [3]. Among many pro- and anti-oxidative enzymes, the NAD+-dependent sirtuins play an important role in stress response [9,39,58]. These enzymes, depending on stress conditions, may exert a neuroprotective effect or may lead to the cell degeneration and death [20,21,25,37,49]. SIRTs are a family of seven enzymes that are type III histone deacetylases (HDAC). Three of them (SIRT3, SIRT4, SIRT5) primarily exist in mitochondria. SIRT1, mainly a nuclear enzyme, can be also present in mitochondria [21]. SIRT1 is one of most-studied and recognized sirtuins, which plays an important role in regulation of oxidative defense, inflammatory response and cells’ fate. SIRT1 levels are downregulated in the AD brain and its expression correlates with the stage/duration of the disease. Moreover, downregulation of SIRT1 parallels with the accumulation of tau protein in AD [22,29]. SIRT1 is also partially involved in reduction of A formation by activation of ADAM10 (-secretase) and promotion of a non-amyloidogenic pathway. Moreover, SIRT1 may revert the negative consequences of A-generated oxidative stress by the increase in mRNA and protein levels of anti-oxidative enzymes, such as manganese superoxide dismutase (SOD2), catalase (Cat), peroxiredoxin 5 (Prx5) and thioredoxin reductase 2 (TR2) [41,47,57]. SIRT1 could also be responsible for reduction of A-induced inflammation via inhibition of the NF-B-dependent gene expression [5,37]. Recent data of in vitro studies have shown that SIRT1 could also downregulate BACE1 expression levels and thus decrease A levels [32]. SIRT1 is also an important regulator of Tau-protein phosphorylation – one of the pathological hallmarks of AD [36].
In this study, we investigated the effect of C2-ceramide and S1PR1 agonist (SEW 2871) on cells’ viability and gene expression of enzymes, which are responsible for APP metabolism and stress response (NAD+-dependent nuclear Sirt1). The studies were carried out using empty vector-transfected cells (PC12), cells transfected with the human wild-type APP gene (APPwt), and cells transfected with a Swedish mutation of the APP gene (APPsw).

Material and methods

Cell culture

Rat pheochromocytoma PC12 cells transfected with a human gene for APP wild-type (APPwt) and cells transfected with a Swedish mutation of Homo sapiens Beta-Amyloid Precursor Protein Gene (K670M/N671L) APP gene (APPsw) were used in this study. Cells transfected with an empty vector was used as a control. PC12 cells were a kind gift from Prof. Arkadiusz Orzechowski (Warsaw University of Life Sciences, Warsaw, Poland). The procedure of cell transfection was described previously [43]. The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 5% heat-inactivated horse serum (HS), 2 mM L-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, gentamicin sulfate 20 µg/ml and Fungizone (amphotericin B, 1 µg/ml). G-418 (400 µg/ml) and ampicillin (100 µg/ml) were additionally present in the medium for growth and selection of positively transfected PC-12 cells. Cells were cultured at 37°C in a 5% CO2 atmosphere.

Cell treatment protocols

The cells were used for experiments between 5 and 12 passage numbers. Prior to treatment, the cells were cultivated in a low serum (2% FBS) medium containing 1% penicillin/streptomycin and 2 mM L-glutamine in order to stop proliferation of cells. Then, PC12 cells were treated with (25 µM) C2-ceramide or/and with (10 µM) SEW 2871 for 24 h. The cells in the C2-ceramide + SEW 2871 group were treated with SEW 2871 one hour prior to the C2-ceramide treatment.

Cell viability analysis using MTT test

Cellular viability was evaluated using 2-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). After incubation with the appropriate compounds, MTT (2.5 mg/ml) was added to all of the wells. The cells were incubated at 37°C for 2 h. Then the medium was removed, formazan crystals were dissolved in DMSO and measurement of absorbance at 595 nm was performed.

Quantitative real-time PCR assays

PC12 cells were washed twice with ice-cold PBS and suspended in 1 ml of TRI reagent (Sigma-Aldrich). Then, RNA was isolated according to the manufacturer’s protocol. The concentration and purity of RNA were assessed spectrophotometrically (A260/A280 method). Digestion of DNA contamination was performed by using DNase I according to the manufacturer’s protocol (Sigma-Aldrich). Reverse transcription was performed using a High Capacity cDNA Reverse Transcription Kit according to the manufacturer’s protocol (Applied Biosystems, Foster City, CA, USA). The level of mRNA for selected genes was analyzed using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) on Applied Biosystems 7500 Real-Time PCR System using TaqMan Gene Expression Master Mix according to the manufacturer’s instructions. The following TaqMan assays were used: Sirt1 (Rn01428096_m1), Adam10 (Rn01530753_m1), Bace1 (Rn00569988_m1), Psen1 (Rn00569763_m1). Actb (Rn00667869_m1) was selected and used in all of the studies as a reference gene. The relative level of mRNA was calculated using the ∆∆Ct method.

Statistical analysis

The presented data are the means ± SEM. For statistical comparisons, one-way ANOVA followed by Newman-Keuls post-hoc test were used. P values < 0.05 were considered statistically significant (*, #p < 0.05; **, ##p < 0.01; ***, ###p < 0.001). The statistical analyses were performed using Graph Pad Prism version 6.0 (Graph Pad Software, San Diego, CA, USA).


In the first step of our research we investigated the cells’ viability after C2-ceramide treatment. It was observed that C2-ceramide induced cell death in both APP-transfected cells and in PC12 control cells with an empty vector. The S1PR1 agonist (SEW 2871) enhanced cells’ viability affected by C2-ceramide (Fig. 1A-C). Then, the effect of C2-ceramide and SEW 2871 on the gene expression of APP metabolizing enzymes which regulate A concentration was analyzed. It was observed that C2-ceramide alone significantly decreased the Adam10 mRNA level in PC12 cells with an empty vector (Fig. 2A). Moreover, S1PR1 agonist significantly enhanced the mRNA level of Adam10 after C2-ceramide treatment (Fig. 2A). A similar, though not significant, tendency was also observed in APP transfected cells (Fig. 2B,C).
In the next step of our research we investigated the influence of C2-ceramide and S1PR1 agonist on the expression of enzymes responsible for APP processing in amyloidogenic pathway. It was found that C2-ceramide exerted a stimulatory effect, though not significant, on the gene expression of -secretase (Bace1) in PC12 control (with empty vector) and APPwt cells (Fig. 3A,B). This effect was not observed in APPsw cells (Fig. 3C). In APPsw cells, SEW 2871 significantly increased the mRNA level of Bace1 only in the presence of C2-ceramide (Fig. 3C).
Additional analysis of ceramide action on APP processing indicated a stimulatory, though not significant, effect of C2-ceramide on the gene expression of Psen1 in APPwt cells (Fig. 4A). Also, in APPsw cells, the mRNA level of Psen1 after C2-ceramide treatment increased significantly (Fig. 4B). This effect was not observed in PC12 control cells with an empty vector (data not shown). Moreover, SEW 2871 had also a significant stimulatory effect on Psen1 mRNA levels in the presence of C2-ceramide in APPsw cells (Fig. 4B). Subsequently, we analyzed the role of the C2-ceramide and S1PR1 agonist in regulation/alterations of the gene expression of stress response proteins such as NAD+ dependent Sirt1 in PC12 cells with overexpressed human APP. We observed small insignificant changes in the mRNA level of Sirt1 after C2-ceramide treatment. However, the S1PR1 agonist in the presence/absence of C2-ceramide exerted significant activation of Sirt1 in APP transfected PC12 cells (Fig. 5B,C).


In our study we have observed decreased cells’ viability after ceramide treatment in all cells’ lines used in the experiment. Concomitantly, the use of SEW 2871 significantly increased the viability of APP-transfected cells as well as control cells (with an empty vector). These results point out the importance of bioactive sphingolipids, especially S1P-mediated signaling as a protection against cell death. In the presented study S1PR1 agonist improved cells’ viability in PC12 control cells with an empty vector and in APP-transfected cells after ceramide treatment.
It has been published that SIRT1 shifts the balance between amyloidogenic and non-amyloidogenic processing of APP in vitro and in transgenic mouse models [37,56]. SIRT1 up-regulates the -secretase ADAM10, and through inhibition of NF-B downregulates the expression of the -secretase (BACE1) [8,27,53]. In vitro studies on human cells’ lines and rat primary cortical neurons have shown that -secretase is also regulated by SIRTs [60]. SIRT1 occurs to reduce the level of A, oxidative stress and in consequence neuronal loss [14]. Our results demonstrated that S1PR1 agonist, SEW 2871, in the presence of C2-ceramide significantly increased the mRNA level of Sirt1 in both transfected cells’ lines. These data correlate with a recent study of Gao et al. [13] where Sphk1 inhibition results in SIRT1 downregulation. Moreover, this effect could be reversed by addition of exogenous S1P. Authors suggest that upregulation of SIRT1 may be mediated by alteration of phosphorylation levels of P38 MAPK, ERK and AKT [13]. Another in vivo study reveals that the activation of sirtuins expression by resveratrol may result in an enhanced level of S1P [24]. These results suggest the important link between S1P and SIRT1 expression.
The results of our study show that the mRNA level of Adam10 is downregulated in PC12 control cells and it shows a tendency to be decreased in APPwt and APPsw cells after C2-ceramide treatment. At the same time, the mRNA expression of Sirt1 does not change in the presence of C2-ceramide. However, the use of SEW2871 leads to an increased expression of Adam10 during C2-ceramide stress in cells with an empty vector and also show a tendency to increase its expression levels in APP-transfected cells. This result points out the modulatory role of S1PR1 on -secretase gene expression during stress conditions evoked by C2-ceramide. This result may also be a consequence of elevated Sirt1 expression after modulatory action of SEW 2871 on the S1PR1. The recent data provide a lot of evidence that exogenous addition of ceramide and/or increased level of endogenous ceramide (induced by de novo synthesis or sphingomyelin hydrolysis) increase the level of A [31,46,50]. Processing of APP to A peptide occurs predominantly in lipid rafts and BACE1 is a rate-limiting enzyme in this process. Membrane ceramides embedded in lipid rafts facilitate production of A by increasing the half-life of BACE1 through posttranslational stabilization [42,46]. In our current study we indicated that C2-ceramide leads to activation of genes coding enzymes responsible for APP metabolism. C2-ceramide enhanced the mRNA level of Psen1 crucial subunit of -secretase involved in degradation of APP in both APP-transfected cells’ lines. Moreover, C2-ceramide exerted a tendency to increase Bace1 gene expression in APPwt cells. It is documented that oxidative stress can stimulate BACE1 expression in cells through the c-jun N-terminal kinase pathway in a mechanism which requires the presence of presenilin [52]. A lot of data also showed that C2-ceramide induced oxidative stress and activated the c-jun kinase pathway [2,11,59]. It is highly possible that in our research the regulation of BACE1 expression occurred through these pathways. Literature data show that another cell-permeable analog of ceramide – C6-ceramide increases the rate of A biosynthesis by affecting -cleavage of APP [46]. It was also documented that synthetic ceramide analogues may influence APP metabolism through its modulatory effect on -secretase activity [50]. Thus, it seems to be very important to maintain the right balance between ceramide and pro-survival molecule S1P. The use of S1P receptor modulators seems to be a promising strategy in counteracting the negative effects of elevated ceramide and amyloidogenic APP enzyme levels. In our study, S1PR1 agonist SEW2871 alters the expression of genes involved with APP processing, which may suggest that SEW2871 accelerates APP/A metabolic rate.
There are a few scientific data about the S1P action on APP degrading enzymes. Takasugi et al. [51] revealed the correlation between Sphk2 and APP processing, where S1P pool produced by Sphk2 may activate -secretase (Bace1) and lead to a higher generation of A peptide [51]. The data from in vitro studies showed that S1P could increase the activity of ADAM17 which also possesses the properties of -secretase [17].
Summarizing, the role of S1P in the regulation of enzymes involved in APP metabolism is complex and poorly understood. S1P may exert its effect not only by activation of its specific receptors, but also acting as a secondary messenger and regulator of the gene expression.


The authors’ work is supported by NCN grant no. 2013/11/N/NZ4/02233.


1. Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein -secretases. J Neurosci Res 2003; 74: 342-352.
2. Arboleda G, Cárdenas Y, Rodríguez Y, Morales LC, Matheus L, Arboleda H. Differential regulation of AKT, MAPK and GSK3 during C2-ceramide-induced neuronal death. Neurotoxicology 2010; 31: 687-693.
3. Butterfield DA, Swomley AM, Sultana R. Amyloid -peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal 2013; 19: 823-835.
4. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 2001; 4: 233-234.
5. Cao L, Liu C, Wang F, Wang H. SIRT1 negatively regulates amyloid-beta-induced inflammation via the NF-kappaB pathway. Braz J Med Biol Res 2013; 46: 659-669.
6. Ceccom J, Loukh N, Lauwers-Cances V, Touriol C, Nicaise Y, Gentil C, Uro-Coste E, Pitson S, Maurage CA, Duyckaerts C, Cuvillier O, Delisle M-B. Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease. Acta Neuropathol Commun 2014; 2: 12.
7. Chakrabarti SS, Bir A, Poddar J, Sinha M, Ganguly A, Chakrabarti S. Ceramide and sphingosine-1-phosphate in cell death pathways: relevance to the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 2016; 13: 1232-1248.
8. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280: 40364-40374.
9. Cieslik M, Czapski GA, Strosznajder JB. The molecular mechanism of amyloid beta42 peptide toxicity: the role of sphingosine kinase-1 and mitochondrial sirtuins. PLoS One 2015; 10: e0137193.
10. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci U S A 2004; 101: 2070-2075.
11. Czubowicz K, Strosznajder R. Ceramide in the molecular mechanisms of neuronal cell death. The role of sphingosine-1-phosphate. Mol Neurobiol 2014; 50: 26-37.
12. Filippov V, Song MA, Zhang K, Vinters HV, Tung S, Kirsch WM, Yang J, Duerksen-Hughes PJ. Increased ceramide in brains with Alzheimer’s and other neurodegenerative diseases. J Alzheimer’s Dis 2012; 29: 537-547.
13. Gao Z, Wang H, Xiao F-J, Shi X-F, Zhang Y-K, Xu QQ, Zhang X-Y, Ha X-Q, Wang L-S. SIRT1 mediates Sphk1/S1P-induced proliferation and migration of endothelial cells. Int J Biochem Cell Biol 2016; 74: 152-160.
14. Godoy JA, Zolezzi JM, Braidy N, Inestrosa NC. Role of Sirt1 during the ageing process: relevance to protection of synapses in the brain. Mol Neurobiol 2014; 50: 744-756.
15. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9: 139-150.
16. Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. Biochim Biophys Acta 2010; 1801: 878-886.
17. Hirata N, Yamada S, Shoda T, Kurihara M, Sekino Y, Kanda Y. Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation. Nat Commun 2014; 5: 4806.
18. Jana A, Pahan K. Fibrillar amyloid-β-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer’s disease. J Neurosci 2010; 30: 12676-12689.
19. Jazvinscak Jembrek M, Hof PR, Simic G. Ceramides in Alzheimer’s disease: key mediators of neuronal apoptosis induced by oxidative stress and Abeta accumulation. Oxid Med Cell Longev 2015; 2015: 346783.
20. Jęśko H, Strosznajder RP. Sirtuins and their interactions with transcription factors and poly(ADP-ribose) polymerases. Folia Neuropathol 2016; 3: 212-233.
21. Jęśko H, Wencel P, Strosznajder RP, Strosznajder JB. Sirtuins and their roles in brain aging and neurodegenerative disorders. Neurochem Res 2017; 42: 876-890.
22. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N Jr, Bennett DA, Calon F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 2009; 68: 48-58.
23. Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 2008; 20: 1010-1018.
24. Kurano M, Hara M, Nojiri T, Ikeda H, Tsukamoto K, Yatomi Y. Resveratrol exerts a biphasic effect on apolipoprotein M. Br J Pharmacol 2016; 173: 222-233.
25. Lalla R, Donmez G. The role of sirtuins in Alzheimer’s disease. Front Aging Neurosci 2013; 5: 16.
26. Larson ME, Lesne SE. Soluble Abeta oligomer production and toxicity. J Neurochem 2012; 120 Suppl 1: 125-139.
27. Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, Hong KW, Kim CD. Cilostazol suppresses beta-amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1-coupled retinoic acid receptor-beta. J Neurosci Res 2014; 92: 1581-1590.
28. Lee J-T, Xu J, Lee J-M, Ku G, Han X, Yang D-I, Chen S, Hsu CY. Amyloid- peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004; 164: 123-131.
29. Lutz MI, Milenkovic I, Regelsberger G, Kovacs GG. Distinct patterns of sirtuin expression during progression of Alzheimer’s disease. Neuromolecular Med 2014; 16: 405-414.
30. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingo­sine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012; 22: 50-60.
31. Malaplate-Armand C, Florent-Bechard S, Youssef I. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 2006; 23: 178-189.
32. Marwarha G, Raza S, Meiers C, Ghribi O. Leptin attenuates BACE1 expression and amyloid-beta genesis via the activation of SIRT1 signaling pathway. Biochim Biophys Acta 2014; 1842: 1587-1595.
33. Mencarelli C, Martinez-Martinez P. Ceramide function in the brain: when a slight tilt is enough. Cell Mol Life Sci 2013; 70: 181-203.
34. Mielke MM, Haughey NJ, Bandaru VV, Schech S, Carrick R, Carlson MC, Mori S, Miller MI, Ceritoglu C, Brown T, Albert M, Lyketsos CG. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 2010; 6: 378-385.
35. Mielke MM, Lyketsos CG. Alterations of the sphingolipid pathway in Alzheimer’s disease: new biomarkers and treatment targets? Neuromolecular Med 2010; 12: 331-340.
36. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010; 67: 953-966.
37. Min SW, Sohn PD, Cho SH, Swanson RA, Gan L. Sirtuins in neuro­degenerative diseases: an update on potential mechanisms. Front Aging Neurosci 2013; 5: 53.
38. Morad SA, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer 2013; 13: 51-65.
39. Morris BJ. Seven sirtuins for seven deadly diseases ofaging. Free Radic Biol Med 2013; 56: 133-171.
40. Novgorodov SA, Gudz TI. Ceramide and mitochondria in ische­mia/reperfusion. J Cardiovasc Pharmacol 2009; 53: 198-208.
41. Olmos Y, Sánchez-Gómez FJ, Wild B, García-Quintans N, Cabezudo S, Lamas S, Monsalve M. SirT1 regulation of antioxidant genes is dependent on the formation of a FoxO3a/PGC-1 complex. Antioxid Redox Signal 2013; 19: 1507-1521.
42. Olsen ASB, Fćrgeman NJ. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol 2017; 7. pii: 170069.
43. Pajak B, Kania E, Orzechowski A. Nucleofection of rat pheochromocytoma PC-12 cells with human mutated beta-amyloid precursor protein gene (APP-sw) leads to reduced viability, autophagy-like process, and increased expression and secretion of beta amyloid. Biomed Res Int 2015; 2015: 746092.
44. Panchal M, Gaudin M, Lazar AN, Salvati E, Rivals I, Ayciriex S, Dauphinot L, Dargère D, Auzeil N, Masserini M, Laprévote O, Duyckaerts C. Ceramides and sphingomyelinases in senile plaques. Neurobiol Dis 2014; 65: 193-201.
45. Park JH, Schuchman EH. Acid ceramidase and human disease. Biochim Biophys Acta 2006; 1758: 2133-2138.
46. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 2003; 278: 19777-19783.
47. Ren Y, Du C, Shi Y, Wei J, Wu H, Cui H. The Sirt1 activator, SRT1720, attenuates renal fibrosis by inhibiting CTGF and oxidative stress. Int J Mol Med 2017; 39: 1317-1324.
48. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004; 92: 913-922.
49. Satoh A, Imai S-i, Guarente L. The brain, sirtuins, and ageing. Nat Rev Neurosci 2017; 18: 362-374.
50. Takasugi N, Sasaki T, Shinohara M, Iwatsubo T, Tomita T. Synthetic ceramide analogues increase amyloid-β 42 production by modulating -secretase activity. Biochem Biophys Res Commun 2015; 457: 194-199.
51. Takasugi N, Sasaki T, Suzuki K, Osawa S, Isshiki H, Hori Y, Shimada N, Higo T, Yokoshima S, Fukuyama T, Lee VM, Trojanowski JQ, Tomita T, Iwatsubo T. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci 2011; 31: 6850-6857.
52. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M. Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 2008; 104: 683-695.
53. Theendakara V, Patent A, Peters Libeu CA, Philpot B, Flores S, Descamps O, Poksay KS, Zhang Q, Cailing G, Hart M, John V, Rao RV, Bredesen DE. Neuroprotective Sirtuin ratio reversed by ApoE4. Proc Natl Acad Sci U S A 2013; 110: 18303-18308.
54. van Echten-Deckert G, Walter J. Sphingolipids: critical players in Alzheimer’s disease. Prog Lipid Res 2012; 51: 378-393.
55. Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, Mc­-Graw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VVR, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain 2014; 137: 2271-2286.
56. Wang J, Fivecoat H, Ho L, Pan Y, Ling E, Pasinetti GM. The role of Sirt1: At the crossroad between promotion of longevity and protection against Alzheimer’s disease neuropathology. Biochim Biophys Acta 2010; 1804: 1690-1694.
57. Wang SJ, Zhao XH, Chen W, Bo N, Wang XJ, Chi ZF, Wu W. Sirtuin 1 activation enhances the PGC-1alpha/mitochondrial antioxidant system pathway in status epilepticus. Mol Med Rep 2015; 11: 521-526.
58. Wencel PL, Lukiw WJ, Strosznajder JB, Strosznajder RP. Inhibition of poly(ADP-ribose) polymerase-1 enhances gene expression of selected sirtuins and APP cleaving enzymes in amyloid beta cytotoxicity. Mol Neurobiol 2018; 55: 4612-4623.
59. Willaime-Morawek S, Brami-Cherrier K, Mariani J, Caboche J, Brugg B. C-Jun N-terminal kinases/c-Jun and p38 pathways cooperate in ceramide-induced neuronal apoptosis. Neuroscience 2003; 119: 387-397.
60. Wu F, Schweizer C, Rudinskiy N, Taylor DM, Kazantsev A, Luthi-Carter R, Fraering PC. Novel gamma-secretase inhibitors uncover a common nucleotide-binding site in JAK3, SIRT2, and PS1. FASEB J 2010; 24: 2464-2474.
61. Xing Y, Tang Y, Zhao L, Wang Q, Qin W, Zhang JL, Jia J. Plasma ceramides and neuropsychiatric symptoms of Alzheimer’s disease. J Alzheimers Dis 2016; 52: 1029-1035.
62. Zhao Y, Bhattacharjee S, Jones BM, Hill JM, Clement C, Samba­murti K, Dua P, Lukiw WJ. Beta-amyloid precursor protein (betaAPP) processing in Alzheimer’s disease (AD) and age-related macular degeneration (AMD). Mol Neurobiol 2015; 52: 533-544.
Copyright: © 2018 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe